Independent IRB vs. Institutional IRB for a Retatrutide Program: Which Is Right for Your Practice

One of the first practical questions in establishing a retatrutide research program is which IRB to use. For most private practices, the choice is between an independent (commercial) IRB and an institutional IRB affiliated with a hospital or academic medical center. Understanding the differences — in cost, timeline, process, and ongoing relationship — is essential for making the right choice.

Institutional IRBs are review boards operated by hospitals, academic medical centers, and research universities. They were designed to review research conducted by investigators affiliated with those institutions — faculty researchers, hospital-based physicians, and graduate students conducting thesis research.

Most private practice physicians are not affiliated with an institution that has its own IRB. And even for physicians who have hospital privileges, institutional IRBs typically require that the research be conducted under the auspices of the institution — which creates administrative complexity and may require institutional co-investigators or institutional oversight that is not practical for a private practice program.

For most private practice owners building a retatrutide research program, an institutional IRB is not the right choice.

Independent IRBs — also called commercial IRBs or central IRBs — are for-profit entities that provide IRB review services to sponsors and investigators who are not affiliated with an institution. They are registered with the FDA and operate under the same federal regulations as institutional IRBs.

Independent IRBs were specifically designed to serve the needs of private practice investigators, pharmaceutical sponsors running multi-site trials, and other researchers who need IRB review outside of an institutional context. They are the standard choice for private practice retatrutide programs.

The process for obtaining IRB approval from an independent IRB typically follows this sequence:

1. Protocol development: You (with your healthcare counsel) develop the research protocol, the informed consent document, and any other study materials.
2. Submission: You submit the protocol package to the IRB, along with the required application forms and fees.
3. Review: The IRB reviews the submission. Depending on the risk level of the research, this may be a full board review (required for greater-than-minimal-risk research) or an expedited review.
4. Approval or revision request: The IRB either approves the protocol or requests revisions. Most first submissions require at least minor revisions.
5. Approval letter: Once approved, the IRB issues an approval letter that authorizes you to begin enrolling research subjects.

The timeline from submission to approval is typically 4–8 weeks for a full board review, or 2–4 weeks for an expedited review.

Independent IRB fees vary by provider and by the complexity of the research. For a single-site, single-investigator retatrutide research program, expect to pay:

• Initial review fee: $1,500–$4,000 for the initial protocol review and approval
• Annual continuing review fee: $500–$2,000 per year for the annual review required to maintain approval
• Amendment fees: $300–$1,000 per amendment (for protocol changes, new sites, etc.)

These fees are modest relative to the revenue potential of a retatrutide program and the liability protection that proper IRB oversight provides.

Not all independent IRBs are equal. When selecting an IRB for your retatrutide program, look for:

• FDA registration: Confirm the IRB is registered with the FDA's Office for Human Research Protections (OHRP) database.
• Experience with investigational peptide research: An IRB that has reviewed similar protocols will have a more efficient review process and more relevant expertise.
• Responsive communication: The IRB relationship is ongoing — you will need to communicate with them for amendments, adverse event reports, and annual reviews. Responsiveness matters.
• Clear fee schedule: Understand all fees upfront, including amendment fees and continuing review fees.